Incidence of human cytomegalovirus infection and T-cell response in patients with psoriasis before and during antitumour necrosis factor-α therapy

Br J Dermatol. 2017 Dec;177(6):e323-e324. doi: 10.1111/bjd.15650. Epub 2017 Nov 29.

Authors

L Fornara¹, C Fornara², R Cananzi¹, D Lilleri², M Furione³, V Brazzelli¹

Affiliations

¹ SC Clinica Dermatologica, Fondazione IRCCS Policlinico S. Matteo, Università degli Studi di Pavia, Pavia, Italy.
² Laboratori Sperimentali di Ricerca Area Trapiantologica, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy.
³ SC Microbiologia e Virologia, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy.

PMID: 28494092
DOI: 10.1111/bjd.15650

No abstract available

Publication types

Letter

MeSH terms

Adalimumab / therapeutic use
Adult
Aged
CD4-Positive T-Lymphocytes / immunology
CD8-Positive T-Lymphocytes / immunology
Case-Control Studies
Cytomegalovirus Infections / immunology*
Etanercept / therapeutic use
Female
Humans
Immunity, Cellular / physiology*
Infliximab / therapeutic use
Male
Middle Aged
Psoriasis / drug therapy*
Psoriasis / immunology
Psoriasis / virology
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Virus Activation / immunology
Young Adult

Substances

Tumor Necrosis Factor-alpha
Infliximab
Adalimumab
Etanercept